CTS CORPORATION
At today's price, CTS CORPORATION (CTS) is priced for +21.6% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
The one number that flips the verdict: diversified end markets, medical, industrial, and aerospace and defense, now make up more than half of revenue and grew 18% in Q1 2026, while transportation grew just 3%. CTS is no longer the cyclical auto-parts supplier its multiple history implies. The balance sheet is a fortress. CTS carries no gross debt and about $91 million of net cash, with interest covered roughly 23 times, which gives it room to keep acquiring without strain. At $66.95 the price
Is CTS overvalued? See what's priced in →
232 institutional managers reported holding CTS in 13F filings for the quarter ended 2026-03-31. Together they hold about 95% of the company; the top 10 hold 59%. 42 opened new positions that quarter. Held by BlackRock, Vanguard Group, Dimensional Fund Advisors, among others. On the short side, 621k shares were sold short as of the 2026-06-15 count, about 2% of shares outstanding (2 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
CTS has cut its share count 11.4% over the past five years, spending $179.81M on repurchases. It pays a dividend, and has paid one every year in our records (16 and counting); the current rate is $0.16 a share annually. Cash returned over the past three years: $13.29M in dividends and $132.01M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at CTS over the trailing three years. Absence is a fact about the company, not a signal. 13 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
CTS's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-07-26 | +1.0% | -4.5% |
| 2023-10-27 | -4.2% | +19.2% |
| 2024-02-24 | +7.1% | +2.5% |
| 2024-05-02 | +6.0% | +2.8% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
CTS's latest 8-K filings: 2026-06-25 (items 5.02); 2026-05-19 (items 5.07); 2026-04-29 (items 7.01, 9.01); 2026-04-29 (items 2.02, 7.01, 9.01); 2026-02-10 (items 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.